Navigation Links
New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
Date:12/9/2010

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation.(1)  The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

The LUX-Lung 1 trial compared afatinib to placebo in 585 patients with advanced NSCLC whose disease progressed after receiving chemotherapy and a first-generation EGFR tyrosine kinase-inhibitor (TKI), gefitinib or erlotinib. In the study, afatinib did not extend the primary endpoint of overall survival in these advanced NSCLC patients.(2)  In addition, patients in the subgroup receiving afatinib did not have a statistically significant increase in overall survival compared to placebo. The authors concluded that the overall survival endpoint may have been confounded by the use of extensive subsequent systematic therapies.(2)  The subgroup included in the new analysis comprised two-thirds of all patients from the study (385/585) who were most likely to have EGFR mutations, as determined by clinical criteria based on their response to and duration of prior treatment with EGFR-TKIs.(1) These findings build upon the initial results from the LUX-Lung 1 clinical trial presented at the recent European Society for Medical Oncology (ESMO) meeting in Milan.(2)

The two most common side effects associated with treatment with afatinib in the LUX-Lung 1 trial were diarrhea (87% all grades, with 17% Grade 3) and rash/acne (79% all grades, with 14% Grade 3).  These side effects were usually well-managed by supportive care and dose reduction.(2)

"We continue to be encouraged by the findings o
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... , August 28, 2015 The scientific ... collaboration with one of the leading academics in the field ... world record holder in life extension for model animals - ... biology of aging and age-related diseases, primarily, around the stability ... has just been published as "Stability analysis of a model ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
... PARIS and NEW DELHI, India, Sept. 20 ... subsidiary of Cellectis (Alternext: ALCLS), and Helix BioService ... that they will join forces for the promotion ... India. Helix Biocon is a young company comprised ...
... A unit of the Government of Ukraine today ... a U.S. company that is alleged to be part ... vaccines and other pharmaceuticals.  The case was brought by ... procurement and storage of medicines and medical supplies for ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3Ukrainian Government Unit Sues in U.S. - Alleges Corrupt Scheme in Vaccine Purchases 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... abuse, or those who might personally be struggling with chemical dependency, may be ... from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located in ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
(Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now ... shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. ... of Illinois, and then went on to earn his title of Doctor of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, ... all for a good cause. In its second year, the “Music With A Mission” ... Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to ...
(Date:8/28/2015)... ... 28, 2015 , ... The newest therapy to receive orphan drug status for ... time soon, according to educational website Surviving Mesothelioma. Click here to read their ... for mesothelioma last week from the FDA, will now head into Phase I clinical ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... Dec. 1 MassMutual Retirement Services Division has added ... Nonprofit activity has more than tripled in 2008 compared ... Dan Darby joined MassMutual on December 1 ... reports to M. Palmer Whitney, national managing director, nonprofit ...
... 1 The Food Allergy & Anaphylaxis Network (FAAN) ... CEO, replacing Founder Anne Munoz-Furlong, who is retiring. , ... to FAAN extensive knowledge of anaphylaxis, a severe, potentially ... Senior Director of Marketing, she led the marketing team ...
... supplements can also trigger acute organ failure, study says ... the single largest class of drugs that cause idiosyncratic ... accounts for about 13 percent of cases of acute ... most common cause of death from acute liver failure. ...
... Dry-needling, steroids effective against plantar fasciitis, researchers say ... researchers say they,ve developed a fast, effective, non-invasive ... plantar fasciitis. , Using a combination of "dry-needling" ... say their approach achieved a 95 percent success ...
... as one in five of all Americans who survive a ... emotionally paralyzed survivors of 9/11 and broken up survivors, families. ... lower the chance of developing the disorder, but thanks to ... PTSD may be just around the corner. , Prof. Joseph ...
... will die of AIDS. In fact, nearly 7,000 people die each day ... 1 is World AIDS Day, a day of awareness and outreach to help ... Day 2008 is You Can Make a Difference and ... as well as helping dispel the myths and misconceptions about HIV. , ...
Cached Medicine News:Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:FAAN Names New CEO 2Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:Easing the stress of trauma 2Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2
... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
... ideally suited for high volume stone centers. This ... and an advanced urological table. With the Dornier ... provides successful treatments for a full range of ... URS and PCN procedures are easy. One of ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
Medicine Products: